Improving outcomes for patients with heart, lung and blood diseases
With support from the National Heart, Lung and Blood Institute (NHLBI), the UC CAI advances early-stage drugs, devices and diagnostics toward commercialization to benefit patients with heart, lung and blood diseases.
Innovators receive pilot funds, mentorship and project-management support to develop their technologies. UC CAI is part of a prestigious, national consortium of academic innovators that includes Harvard University and Cleveland Clinic.
The request for proposals is now open and closes Friday, December 20, 2013.
A webinar for potential applicants will be held on Thursday, November 21 at 12:00 pm PST.